FY2025 EPS Estimates for UTHR Boosted by Cantor Fitzgerald

United Therapeutics Corporation (NASDAQ:UTHR) – Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for United Therapeutics in a research report issued on Wednesday, September 10th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will earn $28.70 per share for the year, up from their prior forecast of $28.43. Cantor Fitzgerald has a “Overweight” rating and a $525.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

Several other brokerages also recently weighed in on UTHR. Morgan Stanley dropped their price objective on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. Bank of America boosted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, September 4th. HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a report on Friday, September 5th. Finally, Jefferies Financial Group increased their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $438.85.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $404.84 on Friday. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The stock’s fifty day moving average price is $316.32 and its two-hundred day moving average price is $307.23. The company has a market cap of $18.26 billion, a PE ratio of 15.80, a P/E/G ratio of 6.05 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the prior year, the business posted $5.85 EPS. The business’s revenue was up 11.7% on a year-over-year basis.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Vanguard Group Inc. boosted its holdings in United Therapeutics by 0.3% in the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock valued at $1,374,001,000 after acquiring an additional 15,312 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. boosted its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Assetmark Inc. boosted its stake in shares of United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after purchasing an additional 197,384 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after buying an additional 4,145 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total value of $3,188,400.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $51,811.50. The trade was a 98.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $14,168,409.01. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 128,816 shares of company stock worth $45,836,113. Company insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.